Tobias Keck

Dr. Tobias Keck

University Lübeck
+1
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2009 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
Ulrich Friedrich WellnerUlrich Friedrich Wellner
Ulrich Friedrich Wellner
JSJörg Schubert
Jörg Schubert
UBUlrike C. Burk
Ulrike C. Burk
OSOtto Schmalhofer
Otto Schmalhofer
FZFeng Zhu
Feng Zhu
TBThomas Brabletz
Thomas Brabletz

1 April 2011 in The Lancet
Verified
Journal Article
Closed access
MDMarkus K Diener
Markus K Diener
CSChristoph M Seiler
Christoph M Seiler
IRInga Rossion
Inga Rossion
Jörg KleeffJörg Kleeff
Jörg Kleeff
MGMatthias Glanemann
Matthias Glanemann
MBMarkus W Büchler
Markus W Büchler

1 July 2009 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
PDF file
HRHartwig Riediger
Hartwig Riediger
TKTobias Keck
Tobias Keck
Ulrich Friedrich WellnerUlrich Friedrich Wellner
Ulrich Friedrich Wellner
AHAxel Zur Hausen
Axel Zur Hausen
UAUlrich Adam
Ulrich Adam
FMFrank Makowiec
Frank Makowiec
Survival after surgery of pancreatic cancer is still poor, even after curative resection. Some prognostic factors like the status of the resection margin, lymph node (LN) status, or tumor grading have been identified. However, only few data have been published regarding the prognostic influence of the LN ratio (number of LN involved to number of examined LN). We, therefore, evaluated potential prognostic factors in 182 patients after resection of pancreatic cancer including assessment of LN ratio. Since 1994, 204 patients underwent pancreatic resection for ductal pancreatic adenocarcinoma. Survival was evaluated in 182 patients with complete follow-up evaluations. Of those 182 patients, 88% had cancer of the pancreatic head, 5% of the body, and 7% of the pancreatic tail. Patients underwent pancreatoduodenectomy (85%), distal resection (12%), or total pancreatectomy (3%). Survival was analyzed by the Kaplan–Meier and Cox methods. In all 204 resected patients, operative mortality was 3.9% (n = 8). In the 182 patients with follow-up, 70% had free resection margins, 62% had G1- or G2-classified tumors, and 70% positive LN. Median tumor size was 30 (7–80) mm. The median number of examined LN was 16 and median number of involved LN 1 (range 0–22). Median LN ratio was 0.1 (0–0.79). Cumulative 5-year survival (5-year SV) in all patients was 15%. In univariate analysis, a LN ratio ≥ 0.2 (5-year SV 6% vs. 19% with LN ratio < 0.2; p = 0.003), LN ratio ≥ 0.3 (5-year SV 0% vs. 18% with LN ratio < 0.3; p < 0.001), a positive resection margin (p < 0.01) and poor differentiation (G3/G4; p < 0.03) were associated with poorer survival. In multivariate analysis, a LN ratio ≥ 0.2 (p < 0.02; relative risk RR 1.6), LN ratio ≥ 0.3 (p < 0.001; RR 2.2), positive margins (p < 0.02; RR 1.7), and poor differentiation (p < 0.03; RR 1.5) were independent factors predicting a poorer outcome. The conventional nodal status or the number of examined nodes (in all patients and in the subgroups of node positive or negative patients) had no significant influence on survival. Patients with one metastatic LN had the same outcome as patients with negative nodes, but prognosis decreased significantly in patients with two or more LN involved. Not the lymph node involvement per se but especially the LN ratio is an independent prognostic factor after resection of pancreatic cancers. In our series, the LN ratio was even the strongest predictor of survival. The routine estimation of the LN ratio may be helpful not only for the individual prediction of prognosis but also for the indication of adjuvant therapy and herein related outcome and therapy studies.

1 August 2014 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
PBPeter Bronsert
Peter Bronsert
KEK Enderle‐Ammour
K Enderle‐Ammour
MBM Bader
M Bader
STS Timme
S Timme
MKM Kuehs
M Kuehs
Ulrich Friedrich WellnerUlrich Friedrich Wellner
Ulrich Friedrich Wellner

1 March 2016 in Annals of Surgery
Verified
Journal Article
Open access
TKTobias Keck
Tobias Keck
Ulrich Friedrich WellnerUlrich Friedrich Wellner
Ulrich Friedrich Wellner
MBM. Bahra
M. Bahra
FKF. Klein
F. Klein
OSO. Sick
O. Sick
UHU. T. Hopt
U. T. Hopt
To assess pancreatic fistula rate and secondary endpoints after pancreatogastrostomy (PG) versus pancreatojejunostomy (PJ) for reconstruction in pancreatoduodenectomy in the setting of a multicenter randomized controlled trial. PJ and PG are established methods for reconstruction in pancreatoduodenectomy. Recent prospective trials suggest superiority of the PG regarding perioperative complications. A multicenter prospective randomized controlled trial comparing PG with PJ was conducted involving 14 German high-volume academic centers for pancreatic surgery. The primary endpoint was clinically relevant postoperative pancreatic fistula. Secondary endpoints comprised perioperative outcome and pancreatic function and quality of life measured at 6 and 12 months of follow-up. From May 2011 to December 2012, 440 patients were randomized, and 320 were included in the intention-to-treat analysis. There was no significant difference in the rate of grade B/C fistula after PG versus PJ (20% vs 22%, P = 0.617). The overall incidence of grade B/C fistula was 21%, and the in-hospital mortality was 6%. Multivariate analysis of the primary endpoint disclosed soft pancreatic texture (odds ratio: 2.1, P = 0.016) as the only independent risk factor. Compared with PJ, PG was associated with an increased rate of grade A/B bleeding events, perioperative stroke, less enzyme supplementation at 6 months, and improved results in some quality of life parameters. The rate of grade B/C fistula after PG versus PJ was not different. There were more postoperative bleeding events with PG. Perioperative morbidity and mortality of pancreatoduodenectomy seem to be underestimated, even in the high-volume center setting.

1 January 2019 in Annals of Surgery
Verified
Journal Article
Closed access
PDF file
JHJony van Hilst
Jony van Hilst
TRThijs de Rooij
Thijs de Rooij
SKSjors Klompmaker
Sjors Klompmaker
MRMajd Rawashdeh
Majd Rawashdeh
FAFrancesca Aleotti
Francesca Aleotti
Mohammed Abu HilalMohammed Abu Hilal
Mohammed Abu Hilal
Objective: The aim of this study was to compare oncological outcomes after minimally invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) in patients with pancreatic ductal adenocarcinoma (PDAC). Background: Cohort studies have suggested superior short-term outcomes of MIDP vs. ODP. Recent international surveys, however, revealed that surgeons have concerns about the oncological outcomes of MIDP for PDAC. Methods: This is a pan-European propensity score matched study including patients who underwent MIDP (laparoscopic or robot-assisted) or ODP for PDAC between January 1, 2007 and July 1, 2015. MIDP patients were matched to ODP patients in a 1:1 ratio. Main outcomes were radical (R0) resection, lymph node retrieval, and survival. Results: In total, 1212 patients were included from 34 centers in 11 countries. Of 356 (29%) MIDP patients, 340 could be matched. After matching, the MIDP conversion rate was 19% (n = 62). Median blood loss [200 mL (60–400) vs 300 mL (150–500), P = 0.001] and hospital stay [8 (6–12) vs 9 (7–14) days, P < 0.001] were lower after MIDP. Clavien-Dindo grade ≥3 complications (18% vs 21%, P = 0.431) and 90-day mortality (2% vs 3%, P > 0.99) were comparable for MIDP and ODP, respectively. R0 resection rate was higher (67% vs 58%, P = 0.019), whereas Gerota's fascia resection (31% vs 60%, P < 0.001) and lymph node retrieval [14 (8–22) vs 22 (14–31), P < 0.001] were lower after MIDP. Median overall survival was 28 [95% confidence interval (CI), 22–34] versus 31 (95% CI, 26–36) months (P = 0.929). Conclusions: Comparable survival was seen after MIDP and ODP for PDAC, but the opposing differences in R0 resection rate, resection of Gerota's fascia, and lymph node retrieval strengthen the need for a randomized trial to confirm the oncological safety of MIDP.